$COLL News

Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

Collegium Pharmaceutical, Inc. 2026 Q2 - Results - Earnings Call Presentation

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance

Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 Reasons to Sell COLL and 1 Stock to Buy Instead

Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness

Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio

Collegium to Participate in 2026 Jefferies Global Healthcare Conference

Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions

Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results

Collegium Pharmaceutical, Inc. 2026 Q1 - Results - Earnings Call Presentation

Collegium Pharmaceutical, Inc. Q1 2026 Earnings Call Summary

Collegium (COLL) Q1 2026 Earnings Transcript